Tech Company Inital Public Offerings
Caribou Biosciences IPO
Headquartered in Berkeley, Caribou Biosciences is now a public company.
Transaction Overview
Company Name
Announced On
7/23/2021
Transaction Type
IPO
Amount
$304,000,000
Proceeds Purpose
We currently intend to use the proceeds to advance the clinical development of our CB-010 product candidate, including funding the ANTLER phase 1 clinical trial through initial data; fund IND-enabling activities and the potential initiation of clinical studies for our CB-011 and CB-012 product candidates; to continue research and development of our iPSC-to-NK platform for solid tumor-targeted cell therapies, advancement of our genome-editing technologies, as well as discovery-stage research toward potential additional programs; and the remainder for working capital and other general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
2929 7th St. 105
Berkeley, CA 94710
USA
Berkeley, CA 94710
USA
Phone
Website
Email Address
Overview
Caribou is a developer of cellular engineering and analysis solutions based on CRISPR technologies. Caribou's tools and technologies provide transformative capabilities to therapeutic development, agricultural biotechnology, industrial biotechnology, and basic and applied biological research.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 7/23/2021: Prodigal venture capital transaction
Next: 7/23/2021: Yoobic venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs